Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

Détails

ID Serval
serval:BIB_FD1D595C2E3A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Editorial
Collection
Publications
Institution
Titre
Genomic Features of Response to Combination Immunotherapy in Lung Cancer.
Périodique
Cancer cell
Auteur(s)
Früh M., Peters S.
ISSN
1878-3686 (Electronic)
ISSN-L
1535-6108
Statut éditorial
Publié
Date de publication
14/05/2018
Peer-reviewed
Oui
Volume
33
Numéro
5
Pages
791-793
Langue
anglais
Notes
Publication types: Journal Article ; Comment
Publication Status: ppublish
Résumé
In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.
Mots-clé
Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Genomics, Humans, Immunotherapy, Lung Neoplasms, Neoplasm Recurrence, Local
Pubmed
Web of science
Création de la notice
17/05/2018 18:11
Dernière modification de la notice
20/08/2019 17:28
Données d'usage